By Helena Smolak
Merck will partner with Chinese biotech Abbisko Therapeutics to market and sell the bone-tumor treatment pimicotinib globally, expanding its commercialization rights for the drug beyond Asia.
The German pharmaceutical company said Friday that it would pay Abbisko an option fee of $85 million.
The companies will explore additional indications for pimicotinib, such as chronic graft-versus-host disease--a systemic disorder where transplanted immune cells recognize the recipient's body as foreign--after a recent late-stage study showed that the treatment significantly improved the response rate compared with placebo among patients with tenosynovial giant cell tumor, a benign tumor that grows around the joints.
Merck entered into an agreement with Abbisko Therapeutics in 2023 for the commercialization rights in Mainland China, Hong Kong, Macau, and Taiwan. Pimicotinib has been granted breakthrough therapy designation by China's National Medical Products Administration and the U.S. Food and Drug Administration.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
March 28, 2025 02:32 ET (06:32 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。